Lantheus (NASDAQ:LNTH) Upgraded by Truist Financial to “Buy” Rating

Truist Financial upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a buy rating in a research note published on Thursday morning, Marketbeat Ratings reports. Truist Financial currently has $80.00 target price on the medical equipment provider’s stock.

A number of other research firms also recently commented on LNTH. B. Riley dropped their price objective on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Finally, TD Cowen lowered their target price on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, September 15th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average target price of $77.33.

Lantheus Trading Up 5.6%

Shares of NASDAQ LNTH traded up $3.52 during mid-day trading on Thursday, hitting $66.62. The company’s stock had a trading volume of 1,549,880 shares, compared to its average volume of 973,316. Lantheus has a one year low of $47.25 and a one year high of $111.29. The company’s fifty day simple moving average is $56.57 and its 200-day simple moving average is $63.18. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The stock has a market cap of $4.42 billion, a price-to-earnings ratio of 27.99 and a beta of -0.10.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. On average, sell-side analysts anticipate that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Lantheus by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after purchasing an additional 115,338 shares during the period. Reinhart Partners LLC. raised its position in Lantheus by 16.4% in the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock valued at $114,905,000 after buying an additional 197,719 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Lantheus by 2.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock valued at $134,534,000 after acquiring an additional 31,454 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Lantheus during the 3rd quarter worth approximately $65,654,000. Finally, Swedbank AB grew its stake in shares of Lantheus by 11.0% during the 1st quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after acquiring an additional 121,500 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.